Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LQ043H
- Development stage
- Unknown
- Lead developer
- Novamab Biopharmaceuticals
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Inhalation
01
Overview
LQ043H is an inhaled VHH nanobody (single-domain antibody) targeting thymic stromal lymphopoietin (TSLP), developed by Novamab Biopharmaceuticals for the treatment of asthma. TSLP is an upstream epithelial-derived cytokine that plays a pivotal role in the inflammatory cascade of asthma, regardless of the underlying phenotype (Th2-high or Th2-low). By delivering the nanobody directly to the lungs via inhalation, LQ043H achieves high local concentrations to neutralize TSLP at the site of inflammation while minimizing systemic exposure and potential side effects. This modality leverages the small size and high stability of camelid-derived VHH fragments, which are well-suited for pulmonary delivery. LQ043H is currently in Phase 1 clinical development, making it one of the first inhaled TSLP-targeting biologics to reach human trials.
- Other names
- LQ043HLQ-043HLQ 043HNovamab TSLP nanobody
02
Targets
TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on LQ043H.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LQ043H.